Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | ERN1 | O75460 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PTGES | O14684 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | MYC | P01106 | 2/20 | 0.46 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29953040 | 1.00 | ALDH1A1 (0.59) | ALDH1A1TP53CA1CA2TDP1 | |
| SCHEMBL78586 | 0.84 | SMN1; SMN2 (0.59) | ALDH1A1TP53CA1CA2TDP1 | |
| SCHEMBL28833440 | 0.82 | ALDH1A1 (0.57) | ALDH1A1TP53CA1CA2TSHR | |
| SCHEMBL11612955 | 0.80 | ALDH1A1 (0.52) | ALDH1A1TP53TDP1SMN1; SMN2HSD17B10 | |
| SCHEMBL2392328 | 0.78 | ABL1 (0.56) | ALDH1A1TDP1ERN1KDM4EHPGD | |
| SCHEMBL31098827 | 0.78 | ABL1 (0.56) | ALDH1A1TDP1ERN1KDM4EHPGD | |
| SCHEMBL11531926 | 0.78 | HPGD (0.51) | ALDH1A1TP53TDP1SMN1; SMN2ERN1 | |
| SCHEMBL2552506 | 0.78 | ALDH1A1 (0.47) | ALDH1A1TP53CA1CA2TDP1 | |
| SCHEMBL3040058 | 0.78 | ERN1 (0.49) | ALDH1A1TP53CA1CA2TDP1 | |
| SCHEMBL436351 | 0.78 | ALDH1A1 (0.48) | ALDH1A1KDM4ECYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-11199544-A | — | — | None | — | — | JP | disclosed |
| JP-11199543-A | — | — | None | — | — | JP | disclosed |
| JP-11246542-A | — | — | None | — | — | JP | disclosed |
| WO-2025103502-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-21 | — | — | US | disclosed |
| EP-4308228-A1 | PLASMA KALLIKREIN INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| CN-117396474-A | Plasma kallikrein inhibitors | 武田药品工业株式会社 | 2024-01-12 | — | — | CN | disclosed |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-05 | — | — | US | disclosed |
| EP-4161905-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | Arbutus Biopharma Corporation (CA) | 2023-04-12 | — | — | EP | disclosed |
| WO-2022197756-A1 | PLASMA KALLIKREIN INHIBITORS | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| EP-1539701-A1 | CASPASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040192612-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-09-30 | — | — | US | disclosed |
| WO-2004058718-A1 | 4-OXO-3-(1-OXO-1H-ISOQUINOLIN-2-YLACETYLAMINO)-PENTANOIC ACID ESTER AND AMIDE DERIVATIVES AND THEIR USE AS CASPASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040072850-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-04-15 | — | — | US | disclosed |
| WO-2004002961-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-01-08 | — | — | WO | disclosed |
| JP-H11246542-A | NEW DICHLOROPHTHALIDE AND ITS PRODUCTION, AND PRODUCTION OF 2-FORMYLBENZOIC ACID NUCLEUS CHLORINATION PRODUCTS USING THE SAME | NIPPON LIGHT METAL CO LTD | 1999-09-14 | — | — | JP | disclosed |
| JP-H11199544-A | PRODUCTION OF BENZENE NUCLEUS-CHLORINATED 2-FORMYLBENZOIC ACID | NIPPON LIGHT METAL CO LTD | 1999-07-27 | — | — | JP | disclosed |
| JP-H11199543-A | PRODUCTION OF BENZENE NUCLEUS-CHLORINATED 2-FORMYLBENZOIC ACID | NIPPON LIGHT METAL CO LTD | 1999-07-27 | — | — | JP | disclosed |
| EP-0576475-B1 | ISOINDOLES HAVING CARDIOVASCULAR ACTIVITY | ITALFARMACO SPA (IT) | 1995-09-20 | — | — | EP | disclosed |
| US-5376673-A | Vasodilation | ITALFARMACO S.P.A. (IT) | 1994-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072850-A1 | Caspase inhibitors and uses thereof | CASP1, CASP5, CASP2 | ALDH1A1 862/4885TP53 282/4885CA1 661/4885 |
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | ALDH1A1 3175/4885TP53 4614/4885CA1 1964/4885 |
| US-20040192612-A1 | Caspase inhibitors and uses thereof | CASP1, CASP3, CASP5 | ALDH1A1 2450/4885TP53 4050/4885CA1 321/4885 |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | NSD3, PML, NSD1 | ALDH1A1 3447/4885TP53 402/4885CA1 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.